Literature DB >> 16041269

Short-term immunosuppression facilitates induction of mixed chimerism and tolerance after bone marrow transplantation without cytoreductive conditioning.

Peter Blaha1, Sinda Bigenzahn, Zvonimir Koporc, Megan Sykes, Ferdinand Muehlbacher, Thomas Wekerle.   

Abstract

BACKGROUND: Induction of mixed chimerism and tolerance usually requires cytoreduction or transplantation of high numbers of bone marrow cells (BMC). However, such protocols have only a suboptimal success rate and, more importantly, equivalent numbers of BMC cannot be routinely obtained in the clinical setting. The authors therefore evaluated whether a short-course of immunosuppression (IS) given in addition to co-stimulation blockade would facilitate chimerism induction and allow reduction of the minimally required number of BMC without cytoreduction.
METHODS: B6 mice received 200, 100, or 50 x 10 unseparated BMC from Balb/c donors plus an anti-CD40L monoclonal antibody (mAb) and CTLA4Ig (without irradiation or cytotoxic drugs). Some groups were treated additionally with IS (rapamycin, methylprednisolone, and mycophenolate mofetil for 4 weeks after bone marrow transplantation), donor-specific transfusion (DST), or anti-OX40L mAb, as indicated.
RESULTS: IS led to long-term multilineage chimerism in 9 of 10 mice receiving 200 x 10 BMC (without IS, 1 of 4; P<0.05), in all mice (n=10) receiving 100 x 10 (without IS, 6 of 9; P<0.05), and notably in 9 of 10 mice treated with 50 x 10 BMC (without IS, 4 of 10; P<0.05). With transient IS, donor skin grafts were accepted longer than 170 days in 9 of 10 mice receiving 200 x 10 (without IS, 0 of 5 mice; P<0.05), all mice receiving 100 x 10 (without IS, 6 of 9; P<0.05), and 6 of 11 mice receiving 50 x 10 BMC (without IS, 4 of 10). The use of DST or anti-OX40L mAb had no beneficial effect.
CONCLUSIONS: Transient IS significantly improves rates of chimerism and donor skin graft survival, and allows lasting mixed chimerism after transplantation of only 50 x 10 BMC. Thus, IS might help in the further development of noncytoreductive chimerism protocols.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16041269     DOI: 10.1097/01.tp.0000164510.25625.70

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

Review 1.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

2.  Combining Treg therapy with mixed chimerism: Getting the best of both worlds.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Chimerism       Date:  2010 Jul-Sep

3.  Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.

Authors:  Carol H Miao; Peiqing Ye; Arthur R Thompson; David J Rawlings; Hans D Ochs
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

4.  IDO-competent-DCs induced by IFN-γ attenuate acute rejection in rat liver transplantation.

Authors:  Xing Sun; Zi-jun Gong; Zhao-wen Wang; Tao Li; Jin-yan Zhang; Hong-cheng Sun; Shuang Liu; Li Huang; Chen Huang; Zhi-hai Peng
Journal:  J Clin Immunol       Date:  2012-03-28       Impact factor: 8.317

Review 5.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 6.  Murine models of transplantation tolerance through mixed chimerism: advances and roadblocks.

Authors:  B Mahr; T Wekerle
Journal:  Clin Exp Immunol       Date:  2017-05-22       Impact factor: 4.330

Review 7.  Influence of immune responses in gene/stem cell therapies for muscular dystrophies.

Authors:  Andrea Farini; Clementina Sitzia; Silvia Erratico; Mirella Meregalli; Yvan Torrente
Journal:  Biomed Res Int       Date:  2014-05-19       Impact factor: 3.411

8.  Murine mobilized peripheral blood stem cells have a lower capacity than bone marrow to induce mixed chimerism and tolerance.

Authors:  Z Koporc; N Pilat; P Nierlich; P Blaha; S Bigenzahn; I Pree; E Selzer; M Sykes; F Muehlbacher; T Wekerle
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

9.  Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance.

Authors:  Paulina Ruiz; Paula Maldonado; Yessia Hidalgo; Daniela Sauma; Mario Rosemblatt; Maria Rosa Bono
Journal:  Front Immunol       Date:  2015-11-23       Impact factor: 7.561

10.  Signal one and two blockade are both critical for non-myeloablative murine HSCT across a major histocompatibility complex barrier.

Authors:  Kia J Langford-Smith; Zara Sandiford; Alex Langford-Smith; Fiona L Wilkinson; Simon A Jones; J Ed Wraith; Robert F Wynn; Brian W Bigger
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.